quizartinib dihydrochloride

View Patient Information

The dihydrochloride salt form of quizartinib, an orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	AC010220 2HCl N-(5-tert-butyl-isoxazol-3-yl)-N'-(4-(7-(2-morpholin-4-ylethoxy)imidazo(2,1-b)(1,3)benzothiazol-2-yl)phenyl)urea dihydrochloride
US brand name:	Vanflyta
Code name:	AC220 2HCl
Chemical structure:	urea, N-(5-(1,1-dimethylethyl)-3-isoxazolyl)-N'-(4-(7-(2-(4-morpholinyl) ethoxy)imidazo(2,1-b)benzothiazol-2-yl)phenyl)-, hydrochloride (1:2)

quizartinib dihydrochloride

Search NCI's Drug Dictionary